RNS & Investor News

SlimBiome® commercial and product development update

08 November 2017

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care provides the following product development and commercial update on its SlimBiome® product platform.

SlimBiome® Product and Application Development

Further to the manufacturing and supply agreement with Knighton Foods announced on 1 November 2017, OptiBiotix is launching a new improved version of its SlimBiome® product platform. The product development has been achieved using Knighton's specialised powder technology which makes SlimBiome® easier to dissolve, greatly enhancing ease of use, flavour and mouthfeel. This will provide a range of new product and application opportunities with partners in the bakery (e.g. in store bakeries), snacking, food service (e.g. coffee shops) and beverage categories and meet growing consumer demand for 'on the go' products.

SlimBiome® Product Range Extension

The new improved SlimBiome® will be sold as an ingredient in white label format, and in OptiBiotix's own brand GoFigure® range of shakes and bars. New flavours and additions to the SlimBiome® and GoFigure® product range will be introduced in early 2018 including morning muesli pots, healthy bites and coffee and tea blends as part of a healthy lifestyle brand. This creates the opportunity for multiple revenue streams from sales of ingredients to food manufacturers, white label products to large retailers, and branded products in multiple presentations to meet the needs of a diverse range of national and international markets. This is all part of a series of ongoing developments with a number of international partners and large retailers to extend SlimBiome's® application into a broader range of 'Health & Wellbeing' food and beverage products.

SlimBiome® Territory Expansion

Further product development is ongoing with a number of international partners to include SlimBiome® in territory specific applications including bakery products (e.g. cookies, tortillas), breakfast cereals (puffs and flakes), food toppings (e.g. salad, breakfast) as well as developing country flavour specific options for healthy snacks, yoghurts and cereal bars. These include Tata with specially formulated and flavoured products ranges for the Asian markets, and a number of US partners looking to improve the health and nutritional status of existing snacking, bakery and cereal products.

Stephen O'Hara, CEO of OptiBiotix, commented: "This announcement updates investors on the significant progress we have made with partners developing new application and product opportunities to extend the use of SlimBiome® across a wider range of products opportunities and territories. We anticipate SlimBiome® being the first in a family of products to include: ImmunBiome, WellBiome, OptiBiome® and CardioBiome®, developed using our advanced microbiome modulating technology platforms, to meet industry and consumer need for scientifically proven products to improve health and wellbeing. As the promise of the microbiome materialises into a wider the range of applications and products and we extend into overseas territories the scale of the opportunity enlarges allowing us to fully exploit the revenue generating potential of our products."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.


For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Jo Turner
Tel: 020 7213 0880
finnCap Broker
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Tel: 020 7220 0500
Walbrook PR Ltd
Anna Dunphy
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001


About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.